Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

DYRK

Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) are conserved serine/threonine kinases. DYRKs have been implicated in cell survival, proliferation and differentiation, and in the pathology of Down Syndrome and Alzheimer's disease.

GNF4877
T114472041073-22-5In house
GNF4877 is a potent inhibitor of DYRK1A and GSK3β (IC50s: 6 nM and 16 nM, respectively), resulting in the blockade of nuclear export of nuclear factor of activated T-cells (NFATc) and increased β-cell proliferation.
  • $127
In Stock
Size
QTY
TargetMol | Inhibitor Hot
HTH-01-091
T241522000209-42-5In house
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM) that also inhibits PIM1 2 3, RIPK2, DYRK3, smMLCK, and CLK2. It can be used to study breast cancer.
  • $296
In Stock
Size
QTY
YK-2-69
T695642619846-89-6In house
YK-2-69 is a highly selective DYRK2 inhibitor with anti-prostate cancer effects.
  • $293 TargetMol
In Stock
Size
QTY
MBM-55
T119602083622-09-5
MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.
  • $187
In Stock
Size
QTY
EHT 1610
T152041425945-60-3In house
EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively. EHT 1610 has an inhibitory effect on leukemia, regulating cell cycle and inducing cell apoptosis.
  • $88
In Stock
Size
QTY
GNF2133
T401872561414-56-8
GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
  • $132
In Stock
Size
QTY
TargetMol | Inhibitor Sale
ML 315
T367071440251-53-5
ML 315 is a selective Clk and DYRK inhibitor with potential anticancer activity for the study of neurological disorders.
  • $44
In Stock
Size
QTY
AZ191
T62571594092-37-1
AZ191(IC50 of 17 nM) is an effective and specific DYRK1B inhibitor. The specificity of AZ191 for DYRK1B is about 5- and 110-fold greater over DYRK1A and DYRK2, respectively.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
LDN-192960
TQ0111184582-62-5
LDN-192960 is a potent inhibitor of Haspin and DYRK2 (IC50s: 10 nM and 48 nM).
  • $133
In Stock
Size
QTY
GSK-626616
T154221025821-33-3
GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
ID-8
T2431147591-46-6
ID-8, a DYRK inhibitor, sustains embryonic stem cell self-renewal in long-term culture.
  • $40
In Stock
Size
QTY
AZ-Dyrk1B-33
T143641679330-37-0
AZ-Dyrk1B-33 (3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine) is a potent and selective Dyrk1B kinase inhibitor with an IC50 of 7 nM.
  • $39
In Stock
Size
QTY
ARN25068
T613602649882-80-2In house
ARN25068 is a potent inhibitor of GSK-3β, FYN, and DYRK1A protein kinases, exerting its activity in the sub-micromolar range. This compound effectively addresses tau hyperphosphorylation [1].
  • $115
In Stock
Size
QTY
INDY
T155791169755-45-6
INDY is an ATP-competitive inhibitor of Dyrk1A and Dyrk1B with IC50s of 0.24 μM and 0.23 μM and a Ki of 0.18 μM for Dyrk1A ATP pocket, respectively.
  • $55
In Stock
Size
QTY
CK2/ERK8-IN-1
T108271085822-09-8In house
CK2/ERK8-IN-1 (TMCB) is a dual inhibitor of casein kinase 2 (CK2) (Ki: 0.25 µM) and ERK8 (IC50s: 0.50 μM) with pro-apoptotic efficacy. CK2/ERK8-IN-1 also binds to PIM1, DYRK1A, and HIPK2 (Kis: 8.65 µM, 11.9 µM, and 15.25 µM).
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CLK-IN-T3
T149802109805-56-1
CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.
  • $53
In Stock
Size
QTY
ProINDY
T23186719277-30-2
ProINDY (Pro-indy) is a potent DYRK inhibitor that activates NFAT for the study of Down syndrome.
  • $92
In Stock
Size
QTY
AnnH31
T26632241809-12-1
AnnH31 is a potent Dyrk1A inhibitor with an IC50 value of 81 nM.AnnH31 inhibits MAO-A with an IC50 of 3.2 μM.AnnH31 can be used as a probe to confirm the involvement of DYRK1A in cellular phosphorylation.
  • $213
In Stock
Size
QTY
CLK1-IN-3
T720392922550-28-3In house
Clk1-in-3 is a + selective and highly potent sexual Clk1 inhibitor with an IC50 of 5 nM and 300 pairs higher affinity than Dyrk1A. CLK1-IN-3 also showed highly effective inhibition of Clk2 and Clk4, with IC50 values of 42 and 108 nM, respectively. CLK1-IN-3 is effective in inducing autophagy in vitro and can be used for prevention and human treatment of acute liver injury (ALI).
  • $106
In Stock
Size
QTY
ML167
T26701285702-20-6
ML167 (CID44968231) is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor.
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Sale
7BIO
T22012916440-85-2
7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
DYRKs-IN-2
T111331386980-04-6
DYRKs-IN-2 has antitumor activity. DYRKs-IN-2 is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively.
  • $2,120
8-10 weeks
Size
QTY
DYRKs-IN-1
T111321387090-01-8
DYRKs-IN-1 has antitumor activity. DYRKs-IN-1 is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 9 nM and 5 nM for DYRK1B and DYRK1A, respectively.
  • $2,870
10-14 weeks
Size
QTY
Protein kinase inhibitors 1
T46361365986-44-2
Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
  • Inquiry Price
1-2 weeks
Size
QTY